Gilead Sciences, Inc. (GILD) PE Ratio: 17.10
Is Gilead Sciences, Inc.’s P/E ratio high or low?
Gilead Sciences, Inc.'s P/E ratio of 17.10 is 85% below its 5-year average of 110.84, near the low end of its 5-year range (10.41–1244.33).
The P/E ratio for Gilead Sciences, Inc. (GILD) is 17.10 as of Tuesday, June 9, 2026. It is below its 12-month average by 19.97% (21.37).
PE Ratio (17.10) = Close Price ($125.50) / Diluted TTM EPS ($7.34)
GILD PE Ratio Chart
GILD Average PE Ratio Chart
GILD Current vs Average PE Ratio Chart
GILD PE Ratio Metrics
PE RATIO
17.10
PE RATIO AVG TTM
21.37
PE RATIO AVG 3Y
157.51
PE RATIO AVG 5Y
110.84
PE RATIO AVG 10Y
84.20
PE RATIO AVG 15Y
62.97
PE RATIO AVG 20Y
54.16
CURRENT VS TTM AVG
-19.97%
CURRENT VS 3Y AVG
-89.14%
CURRENT VS 5Y AVG
-84.57%
CURRENT VS 10Y AVG
-79.69%
CURRENT VS 15Y AVG
-72.84%
CURRENT VS 20Y AVG
-68.43%
GILD Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | — | 17.10 | 21.37 | 157.51 | 110.84 |
| Abbott Laboratories (ABT) | $158.94B | 25.42 | 19.27 | 27.89 | 28.20 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 51.71 | 66.05 | 75.09 | 71.88 |
| Pfizer Inc. (PFE) | $146.48B | 19.62 | 16.35 | 32.11 | 24.42 |
| Danaher Corporation (DHR) | $133.37B | 36.44 | 41.63 | 38.60 | 34.94 |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 27.16 | 29.19 | 32.54 | 31.18 |
| Amgen Inc. (AMGN) | $185.96B | 23.98 | 25.07 | 29.61 | 26.36 |
| CVS Health Corporation (CVS) | $123.84B | 42.76 | 81.70 | 37.69 | 30.74 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 15.87 | 17.64 | 15.36 | 26.07 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 26.44 | 29.60 | 29.59 | 27.82 |
P/E vs. its own history
At 17.1, P/E is in its normal range — richer than 38% of its 20-year range.
20-year low
6.1
median
19.3
20-year high
1244.3
P/E Comparison
Trailing P/E
17.1
Forward P/E
13.0
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$125.50
Forward EPS (Est.)
$9.65
Forward P/E
13.00
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Gilead Sciences, Inc. PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. PE Ratio FAQ
- What is the P/E ratio for Gilead Sciences, Inc. (GILD)?
- The P/E ratio for GILD stock is 17.10.
- Is Gilead Sciences, Inc.'s P/E ratio high or low?
- Gilead Sciences, Inc.'s P/E ratio of 17.10 is 85% below its 5-year average of 110.84, near the low end of its 5-year range (10.41–1244.33).
- What is the TTM average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The TTM average P/E ratio for GILD stock is 21.37.
- What is the 3Y average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The 3Y average P/E ratio for GILD stock is 157.51.
- What is the 5Y average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The 5Y average P/E ratio for GILD stock is 110.84.
- What is the 10Y average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The 10Y average P/E ratio for GILD stock is 84.20.
- What is the 15Y average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The 15Y average P/E ratio for GILD stock is 62.97.
- What is the 20Y average P/E ratio for Gilead Sciences, Inc. (GILD)?
- The 20Y average P/E ratio for GILD stock is 54.16.
Gilead Sciences, Inc. PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-09 | 17.10 |
| 2026-06-08 | 17.45 |
| 2026-06-05 | 17.60 |
| 2026-06-04 | 17.60 |
| 2026-06-03 | 17.57 |
| 2026-06-02 | 17.38 |
| 2026-06-01 | 17.86 |
| 2026-05-29 | 18.31 |
| 2026-05-28 | 18.56 |
| 2026-05-27 | 18.21 |
| 2026-05-26 | 18.22 |
| 2026-05-22 | 18.31 |
| 2026-05-21 | 17.78 |
| 2026-05-20 | 17.81 |
| 2026-05-19 | 17.78 |
| 2026-05-18 | 17.67 |
| 2026-05-15 | 17.65 |
| 2026-05-14 | 17.99 |
| 2026-05-13 | 18.13 |
| 2026-05-12 | 18.38 |
| 2026-05-11 | 18.19 |
| 2026-05-08 | 17.89 |
| 2026-05-07 | 18.26 |
| 2026-05-06 | 20.13 |
| 2026-05-05 | 19.72 |
| 2026-05-04 | 19.60 |
| 2026-05-01 | 19.45 |
| 2026-04-30 | 19.33 |
| 2026-04-29 | 19.03 |
| 2026-04-28 | 19.09 |
| 2026-04-27 | 18.87 |
| 2026-04-24 | 19.26 |
| 2026-04-23 | 19.74 |
| 2026-04-22 | 19.63 |
| 2026-04-21 | 19.69 |
| 2026-04-20 | 20.07 |
| 2026-04-17 | 20.33 |
| 2026-04-16 | 20.47 |
| 2026-04-15 | 20.65 |
| 2026-04-14 | 20.75 |
| 2026-04-13 | 20.54 |
| 2026-04-10 | 20.53 |
| 2026-04-09 | 20.99 |
| 2026-04-08 | 20.91 |
| 2026-04-07 | 20.50 |
| 2026-04-06 | 20.70 |
| 2026-04-02 | 20.64 |
| 2026-04-01 | 20.72 |
| 2026-03-31 | 20.59 |
| 2026-03-30 | 20.14 |
| 2026-03-27 | 19.83 |
| 2026-03-26 | 20.22 |
| 2026-03-25 | 20.42 |
| 2026-03-24 | 20.40 |
| 2026-03-23 | 20.29 |
| 2026-03-20 | 20.27 |
| 2026-03-19 | 20.84 |
| 2026-03-18 | 20.87 |
| 2026-03-17 | 21.33 |
| 2026-03-16 | 21.45 |
| 2026-03-13 | 21.42 |
| 2026-03-12 | 21.45 |
| 2026-03-11 | 21.57 |
| 2026-03-10 | 21.94 |
| 2026-03-09 | 21.66 |
| 2026-03-06 | 21.26 |
| 2026-03-05 | 21.44 |
| 2026-03-04 | 21.89 |
| 2026-03-03 | 21.84 |
| 2026-03-02 | 22.16 |
| 2026-02-27 | 22.00 |
| 2026-02-26 | 21.24 |
| 2026-02-25 | 21.73 |
| 2026-02-24 | 21.81 |
| 2026-02-23 | 23.23 |
| 2026-02-20 | 23.47 |
| 2026-02-19 | 23.43 |
| 2026-02-18 | 23.68 |
| 2026-02-17 | 24.07 |
| 2026-02-13 | 24.03 |
| 2026-02-12 | 23.54 |
| 2026-02-11 | 24.16 |
| 2026-02-10 | 22.83 |
| 2026-02-09 | 23.52 |
| 2026-02-06 | 23.64 |
| 2026-02-05 | 23.16 |
| 2026-02-04 | 22.67 |
| 2026-02-03 | 22.21 |
| 2026-02-02 | 22.15 |
| 2026-01-30 | 22.01 |
| 2026-01-29 | 21.64 |
| 2026-01-28 | 21.66 |
| 2026-01-27 | 21.86 |
| 2026-01-26 | 21.36 |
| 2026-01-23 | 21.07 |
| 2026-01-22 | 20.33 |
| 2026-01-21 | 20.02 |
| 2026-01-20 | 19.25 |
| 2026-01-16 | 19.37 |
| 2026-01-15 | 18.80 |
| 2026-01-14 | 19.24 |
| 2026-01-13 | 18.88 |
| 2026-01-12 | 19.01 |
| 2026-01-09 | 18.78 |
| 2026-01-08 | 18.71 |
| 2026-01-07 | 19.28 |
| 2026-01-06 | 18.82 |
| 2026-01-05 | 18.34 |
| 2026-01-02 | 18.85 |
| 2025-12-31 | 19.03 |
| 2025-12-30 | 19.10 |
| 2025-12-29 | 19.37 |
| 2025-12-26 | 19.33 |
| 2025-12-24 | 19.48 |
| 2025-12-23 | 19.41 |
| 2025-12-22 | 19.25 |
| 2025-12-19 | 19.27 |
| 2025-12-18 | 18.83 |
| 2025-12-17 | 18.82 |
| 2025-12-16 | 18.42 |
| 2025-12-15 | 18.57 |
| 2025-12-12 | 18.67 |
| 2025-12-11 | 19.10 |
| 2025-12-10 | 18.81 |
| 2025-12-09 | 18.51 |
| 2025-12-08 | 18.79 |
| 2025-12-05 | 18.79 |
| 2025-12-04 | 19.01 |
| 2025-12-03 | 19.38 |
| 2025-12-02 | 19.21 |
| 2025-12-01 | 19.28 |
| 2025-11-28 | 19.51 |
| 2025-11-26 | 19.77 |
| 2025-11-25 | 19.71 |
| 2025-11-24 | 19.42 |
| 2025-11-21 | 19.63 |
| 2025-11-20 | 19.38 |
| 2025-11-19 | 19.86 |
| 2025-11-18 | 19.72 |
| 2025-11-17 | 19.24 |
| 2025-11-14 | 19.38 |
| 2025-11-13 | 19.41 |
| 2025-11-12 | 19.13 |
| 2025-11-11 | 19.00 |
| 2025-11-10 | 18.32 |
| 2025-11-07 | 18.42 |
| 2025-11-06 | 24.58 |
| 2025-11-05 | 24.42 |
| 2025-11-04 | 24.50 |
| 2025-11-03 | 24.31 |
| 2025-10-31 | 23.86 |
| 2025-10-30 | 23.59 |
| 2025-10-29 | 23.61 |
| 2025-10-28 | 23.48 |
| 2025-10-27 | 24.00 |
| 2025-10-24 | 24.09 |
| 2025-10-23 | 24.05 |
| 2025-10-22 | 24.20 |
| 2025-10-21 | 24.72 |
| 2025-10-20 | 24.52 |
| 2025-10-17 | 24.46 |
| 2025-10-16 | 23.48 |
| 2025-10-15 | 23.57 |
| 2025-10-14 | 23.60 |
| 2025-10-13 | 23.55 |
| 2025-10-10 | 23.34 |
| 2025-10-09 | 23.25 |
| 2025-10-08 | 23.56 |
| 2025-10-07 | 23.26 |
| 2025-10-06 | 22.63 |
| 2025-10-03 | 22.45 |
| 2025-10-02 | 22.02 |
| 2025-10-01 | 22.14 |
| 2025-09-30 | 22.11 |
| 2025-09-29 | 22.43 |
| 2025-09-26 | 22.33 |
| 2025-09-25 | 22.11 |
| 2025-09-24 | 22.64 |
| 2025-09-23 | 22.79 |
| 2025-09-22 | 22.41 |
| 2025-09-19 | 22.73 |
| 2025-09-18 | 22.63 |
| 2025-09-17 | 22.36 |
| 2025-09-16 | 22.08 |
| 2025-09-15 | 22.42 |
| 2025-09-12 | 22.82 |
| 2025-09-11 | 23.48 |
| 2025-09-10 | 22.96 |
| 2025-09-09 | 23.06 |
| 2025-09-08 | 23.08 |
| 2025-09-05 | 22.92 |
| 2025-09-04 | 22.46 |
| 2025-09-03 | 22.51 |
| 2025-09-02 | 22.45 |
| 2025-08-29 | 22.50 |
| 2025-08-28 | 22.42 |
| 2025-08-27 | 22.69 |
| 2025-08-26 | 22.86 |
| 2025-08-25 | 22.74 |
| 2025-08-22 | 22.86 |
| 2025-08-21 | 23.14 |
| 2025-08-20 | 23.65 |
| 2025-08-19 | 23.50 |
| 2025-08-18 | 23.50 |
| 2025-08-15 | 23.58 |
| 2025-08-14 | 23.71 |
| 2025-08-13 | 23.93 |
| 2025-08-12 | 23.91 |
| 2025-08-11 | 24.00 |
| 2025-08-08 | 23.79 |
| 2025-08-07 | 21.97 |
| 2025-08-06 | 23.22 |
| 2025-08-05 | 23.68 |
| 2025-08-04 | 24.11 |
| 2025-08-01 | 23.83 |
| 2025-07-31 | 23.64 |
| 2025-07-30 | 24.16 |
| 2025-07-29 | 24.05 |
| 2025-07-28 | 23.80 |
| 2025-07-25 | 24.46 |
| 2025-07-24 | 23.83 |
| 2025-07-23 | 23.91 |
| 2025-07-22 | 23.19 |
| 2025-07-21 | 22.80 |
| 2025-07-18 | 22.78 |
| 2025-07-17 | 22.91 |
| 2025-07-16 | 23.13 |
| 2025-07-15 | 22.96 |
| 2025-07-14 | 23.60 |
| 2025-07-11 | 23.08 |
| 2025-07-10 | 24.11 |
| 2025-07-09 | 23.84 |
| 2025-07-08 | 23.38 |
| 2025-07-07 | 23.53 |
| 2025-07-03 | 23.53 |
| 2025-07-02 | 23.48 |
| 2025-07-01 | 23.52 |
| 2025-06-30 | 23.34 |
| 2025-06-27 | 23.30 |
| 2025-06-26 | 22.66 |
| 2025-06-25 | 22.30 |
| 2025-06-24 | 22.57 |
| 2025-06-23 | 22.36 |
| 2025-06-20 | 22.84 |
| 2025-06-18 | 22.74 |
| 2025-06-17 | 22.74 |
| 2025-06-16 | 23.33 |
| 2025-06-13 | 23.15 |
| 2025-06-12 | 23.59 |
| 2025-06-11 | 23.01 |
| 2025-06-10 | 23.18 |
| 2025-06-09 | 23.79 |
| 2025-06-06 | 23.68 |
| 2025-06-05 | 23.25 |
| 2025-06-04 | 22.95 |
| 2025-06-03 | 23.02 |
| 2025-06-02 | 22.93 |
| 2025-05-30 | 23.17 |
| 2025-05-29 | 23.39 |
| 2025-05-28 | 22.83 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day